MX2017014436A - Compuestos biciclicos. - Google Patents
Compuestos biciclicos.Info
- Publication number
- MX2017014436A MX2017014436A MX2017014436A MX2017014436A MX2017014436A MX 2017014436 A MX2017014436 A MX 2017014436A MX 2017014436 A MX2017014436 A MX 2017014436A MX 2017014436 A MX2017014436 A MX 2017014436A MX 2017014436 A MX2017014436 A MX 2017014436A
- Authority
- MX
- Mexico
- Prior art keywords
- bicyclic compounds
- compounds
- ameliorating
- nitrogen
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
En la presente descripción se describen compuestos bicíclicos que contienen nitrógeno, junto con composiciones farmacéuticas y métodos para aliviar y/o tratar un cáncer descrito en la presente descripción con uno o más de los compuestos descritos en la presente descripción.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562160413P | 2015-05-12 | 2015-05-12 | |
PCT/US2016/031663 WO2016183094A1 (en) | 2015-05-12 | 2016-05-10 | Bicyclic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017014436A true MX2017014436A (es) | 2018-08-01 |
Family
ID=57249537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017014436A MX2017014436A (es) | 2015-05-12 | 2016-05-10 | Compuestos biciclicos. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20180201614A1 (es) |
EP (1) | EP3294737A4 (es) |
JP (1) | JP2018515524A (es) |
KR (1) | KR20180003614A (es) |
CN (1) | CN107849036A (es) |
AU (1) | AU2016261730A1 (es) |
BR (1) | BR112017024163A2 (es) |
CA (1) | CA2984496A1 (es) |
HK (1) | HK1252614A1 (es) |
IL (1) | IL255357A0 (es) |
MX (1) | MX2017014436A (es) |
RU (1) | RU2017139771A (es) |
TW (1) | TW201706272A (es) |
WO (1) | WO2016183094A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
HUE056615T2 (hu) | 2017-10-18 | 2022-02-28 | Incyte Corp | Tercier hidroxicsoportokkal szubsztituált kondenzált imidazol-származékok mint PI3K-gamma inhibitorok |
EP3921319B1 (en) * | 2019-02-07 | 2024-03-06 | BeiGene, Ltd. | Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist |
WO2021016263A1 (en) * | 2019-07-21 | 2021-01-28 | University Of Virginia Patent Foundation | Cysteine binding compositions and methods of use thereof |
CN114081889A (zh) * | 2020-12-29 | 2022-02-25 | 上海岸阔医药科技有限公司 | 预防或治疗egfr功能异常相关的副作用的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2587192A1 (en) * | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
JP2011529073A (ja) * | 2008-07-24 | 2011-12-01 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ調節因子として有用な縮合ヘテロ環化合物 |
KR20170013414A (ko) * | 2008-12-08 | 2017-02-06 | 질레드 코네티컷 인코포레이티드 | 이미다조피라진 syk 억제제 |
TW201522332A (zh) * | 2013-03-01 | 2015-06-16 | Amgen Inc | 經取代之7-酮基-吡啶并[2,3-d]嘧啶及其使用方法 |
UA115388C2 (uk) * | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
WO2015157955A1 (en) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
WO2016091916A1 (en) * | 2014-12-10 | 2016-06-16 | F. Hoffmann-La Roche Ag | Pyrazolylaminopurines as itk inhibitors |
-
2016
- 2016-05-10 CA CA2984496A patent/CA2984496A1/en not_active Abandoned
- 2016-05-10 RU RU2017139771A patent/RU2017139771A/ru not_active Application Discontinuation
- 2016-05-10 KR KR1020177035405A patent/KR20180003614A/ko unknown
- 2016-05-10 AU AU2016261730A patent/AU2016261730A1/en not_active Abandoned
- 2016-05-10 WO PCT/US2016/031663 patent/WO2016183094A1/en active Application Filing
- 2016-05-10 EP EP16793375.3A patent/EP3294737A4/en not_active Withdrawn
- 2016-05-10 JP JP2017559002A patent/JP2018515524A/ja active Pending
- 2016-05-10 US US15/572,744 patent/US20180201614A1/en not_active Abandoned
- 2016-05-10 MX MX2017014436A patent/MX2017014436A/es unknown
- 2016-05-10 BR BR112017024163A patent/BR112017024163A2/pt not_active Application Discontinuation
- 2016-05-10 CN CN201680033908.XA patent/CN107849036A/zh active Pending
- 2016-05-12 TW TW105114762A patent/TW201706272A/zh unknown
-
2017
- 2017-10-31 IL IL255357A patent/IL255357A0/en unknown
-
2018
- 2018-09-17 HK HK18111914.0A patent/HK1252614A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20180201614A1 (en) | 2018-07-19 |
HK1252614A1 (zh) | 2019-05-31 |
WO2016183094A1 (en) | 2016-11-17 |
RU2017139771A (ru) | 2019-06-13 |
AU2016261730A1 (en) | 2017-11-16 |
EP3294737A1 (en) | 2018-03-21 |
CA2984496A1 (en) | 2016-11-17 |
BR112017024163A2 (pt) | 2018-07-17 |
TW201706272A (zh) | 2017-02-16 |
IL255357A0 (en) | 2017-12-31 |
EP3294737A4 (en) | 2018-10-03 |
CN107849036A (zh) | 2018-03-27 |
KR20180003614A (ko) | 2018-01-09 |
JP2018515524A (ja) | 2018-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019003938A (es) | Compuestos espirociclicos. | |
MX2021007773A (es) | Compuestos inhibidores de egfr. | |
MX2021000710A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2023007841A (es) | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. | |
MX2019007030A (es) | Composiciones y metodos para el tratamiento del cancer. | |
ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
MX2017001587A (es) | Terapia de combinacion para tratar un paramixovirus. | |
MY187540A (en) | Compounds active towards bromodomains | |
MY192927A (en) | Fused bicyclic compounds for the treatment of disease | |
MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
MX2017008456A (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades. | |
MX2017012553A (es) | Compuestos espirociclicos. | |
MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
MA40457A (fr) | Combinaison de médicaments pour traiter le myélome multiple | |
MX2017014436A (es) | Compuestos biciclicos. | |
MX2019015676A (es) | Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento. | |
MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
JO3488B1 (ar) | مثبط أرورا a كيناز | |
EP3413906A4 (en) | COMBINATION COMPOSITIONS FOR CANCER TREATMENT, METHOD AND USES | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
MX370897B (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades,. | |
PH12018501455A1 (en) | Therapeutic compostions and methods for treating hepatitis b | |
MX2019003755A (es) | Regimen de dosificacion de avelumab para el tratamiento de cancer. | |
MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
MX2018014034A (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: ZENO ROYALTIES & MILESTONES, LLC |